Brief: NGM Bio Presents Findings From 24-Week Phase 2 Study (Cohort 4) Of Aldafermin And Announces Enrollment Completed In Phase 2B Alpine 2/3 Study
29/08/2020 12:49
Aug 29 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM BIO PRESENTS FINDINGS FROM 24-WEEK PHASE 2 STUDY
(COHORT 4)
OF ALDAFERMIN; ANNOUNCES ENROLLMENT COMPLETED IN PHASE 2B ALPINE
2/3 STUDY
* NGM BIOPHARMACEUTICALS - 24-WEEK PHASE 2 STUDY MET ITS
PRIMARY
ENDPOINT, ACHIEVING A STATISTICALLY SIGNIFICANT REDUCTION IN
LIVER FAT CONTENT (LFC)
* NGM BIOPHARMACEUTICALS - NEW ANALYSIS SHOWS 30% PLACEBO
CORRECTED ANTI-FIBROTIC RESPONSE RATE AMONG NASH PATIENTS WITH
MORE ADVANCED LIVER FIBROSIS
* NGM BIO ANTICIPATES PHASE 2B ALPINE 2/3 STUDY TOPLINE DATA
READOUT IN Q2 2021
Source text for Eikon: ID:nGNX3GBq12
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors